There are no adequate and well-controlled studies of Idarucizumab in pregnant women to inform on associated risks. Animal reproductive and development studies have not been conducted with Idarucizumab. It is also not known whether Idarucizumab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Idarucizumab should be given to a pregnant woman only if clearly needed.
